An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy.

Trial Profile

An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2013

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2009 Planned end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 22 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top